GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Qualis Innovations Inc (OTCPK:QLIS) » Definitions » YoY EPS Growth

Qualis Innovations (Qualis Innovations) YoY EPS Growth : 90.00% (As of Mar. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Qualis Innovations YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Qualis Innovations's YoY EPS Growth for the quarter that ended in Mar. 2024 was 90.00%.

Qualis Innovations's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.00.

Qualis Innovations YoY EPS Growth Historical Data

The historical data trend for Qualis Innovations's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qualis Innovations YoY EPS Growth Chart

Qualis Innovations Annual Data
Trend Jul06 Jul07 Jul08 Jul09 Jul10 Dec11 Dec21 Dec22 Dec23
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only 88.53 101.57 -101.25 56.00 18.18

Qualis Innovations Quarterly Data
Oct10 Jan11 Apr11 Sep11 Dec11 Mar12 Jun12 Sep12 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -216.67 85.00 700.00 90.00

Qualis Innovations YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Qualis Innovations's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EPS Growth (A: Dec. 2023 )
=(Earnings per Share (Diluted) (A: Dec. 2023 )-Earnings per Share (Diluted) (A: Dec. 2022 ))/ | Earnings per Share (Diluted) (A: Dec. 2022 ) |
=(-0.09--0.11)/ | -0.11 |
=18.18 %

Qualis Innovations's YoY EPS Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EPS Growth (Q: Mar. 2024 )
=(Earnings per Share (Diluted) (Q: Mar. 2024 )-Earnings per Share (Diluted) (Q: Mar. 2023 )) / | Earnings per Share (Diluted) (Q: Mar. 2023 )) |
=(-0.001--0.01)/ | -0.01 |
=90.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qualis Innovations YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Qualis Innovations's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Qualis Innovations (Qualis Innovations) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Qualis Innovations Inc (OTCPK:QLIS) » Definitions » YoY EPS Growth
Comparable Companies
VYCO TIVC DYNT BBLG NAOV VTAK INBS NXL THMO ESMC ABT SYK MDT BSX SZSE:300760 DXCM EW ZBH STE XAMS:PHIA
Traded in Other Exchanges
N/A
Address
225 Wilmington West Chester Pike, Suite 200, No.145, Chadds Ford, PA, USA, 19317
Website
https://www.qualisinnovations.com
Qualis Innovations Inc. is the holding company of mPathix Health, Inc. The company is focused on the development, production, and distribution of multi-modal pain management and Central Nervous System related solutions. It develops pain management products using a modality agnostic, virtual operating model. The company is developing a product designed to address the unmet needs of patients who seek alternatives to traditional pain medications and interventions or adjunctive therapies to their current treatment regimen.
Executives
Bin Wang director 112 RICO DR. NORTH, MORGANVILLE NJ 07751